Ro 32-4397

prodrug of Ro-32-2313; structure in first source

Also Known As:

Ro-32-4397

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

1.	Infections 01/01/1998 - "It was shown that in vivo administration of Ro 32-4397 (i) significantly reduced the viral titre detected in isolated dorsal root ganglia; (ii) prevented HSV-2-induced lethality in a systemic infection model; and (iii) reduced zosteriform lesion development in a model of dermal infection. "